OBIO

Orchestra BioMed Holdings, Inc. (OBIO) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Orchestra BioMed is a biomedical innovation company focused on two flagship product candidates: AVIM Therapy (for hypertension) and Virtue SAB (for atherosclerotic artery disease). The company operates under a partnership-enabled business model, notably with Medtronic for AVIM Therapy. As of June 30, 2026, the company had 60,105,049 shares of common stock outstanding.

Key Financial Metrics (Six Months Ended June 30, 2026)

Note: Total Debt includes Royalty Purchase Agreement ($34,593), Note Payable ($20,442), and Loan Payable ($14,397).

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 88% to $198,000 from $1.7 million in the prior year period. This was driven by a 100% drop in partnership revenue following the termination of the Terumo Agreement in October 2025 and a 35% decline in product revenue from FreeHold Surgical.
• Increased Operating Loss: Net loss increased 17% to $44.4 million from $38.1 million year-over-year. Operating expenses rose 12% to $44.6 million, primarily due to an 18% increase in R&D expenses ($32.4 million) to support the BACKBEAT and Virtue clinical trials.
• Debt Expansion: The company significantly increased leverage, adding a $20.0 million convertible loan from Medtronic and receiving a second tranche of $15.0 million under the Royalty Purchase Agreement with Ligand Pharmaceuticals.
• One-Time Gain: The company recognized a $2.3 million gain on the sale of strategic investments (Vivasure Medical Limited) following its acquisition by Haemonetics Corporation.

Outlook, Risks, and Management Commentary

• Clinical Progress: The BACKBEAT Global Pivotal Trial for AVIM Therapy is ongoing, with enrollment targeted for completion by Q3 2026. The Virtue Trial for Virtue SAB is expected to complete enrollment in 2027.
• Liquidity Position: Management estimates that current cash and marketable securities ($110.0 million) are sufficient to fund operations into the fourth quarter of 2027. However, the company expects to incur substantial operating losses in the future and may require additional capital.
• Financing Activities: The company raised $40.3 million in net cash from financing activities during the six-month period, including proceeds from the Medtronic loan, the Ligand royalty agreement, and an At-The-Market (ATM) equity offering.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to raise future financing, and the high cost of debt (effective interest rates of ~21.2% on the Royalty Purchase Agreement and ~13.2% on the Medtronic Note).

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the management estimate that current liquidity supports operations through Q4 2027, given the high burn rate (~$41.5 million operating cash outflow in six months).
• Debt Covenants: Review the specific covenants in the 2024 Loan and Security Agreement (Hercules) and the Medtronic Loan Agreement, particularly regarding "Qualified Cash" maintenance requirements starting January 1, 2027.
• Revenue Recognition: Confirm the timeline for potential revenue recognition under the Amended Medtronic Agreement, as no revenue has been recognized to date despite the collaboration.
• Derivative Liability: Monitor the fair value of the derivative liability associated with Series A Preferred Stock, which fluctuates based on stock price and volatility assumptions.
• Clinical Milestones: Track the enrollment status of the BACKBEAT and Virtue trials, as delays could impact funding needs and future revenue projections.